CL2019000405A1 - Vacunas virales. - Google Patents

Vacunas virales.

Info

Publication number
CL2019000405A1
CL2019000405A1 CL2019000405A CL2019000405A CL2019000405A1 CL 2019000405 A1 CL2019000405 A1 CL 2019000405A1 CL 2019000405 A CL2019000405 A CL 2019000405A CL 2019000405 A CL2019000405 A CL 2019000405A CL 2019000405 A1 CL2019000405 A1 CL 2019000405A1
Authority
CL
Chile
Prior art keywords
virus
infection
chikungunya
viruela
zika
Prior art date
Application number
CL2019000405A
Other languages
English (en)
Inventor
Paul Howley
Original Assignee
Sementis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by Sementis Ltd filed Critical Sementis Ltd
Publication of CL2019000405A1 publication Critical patent/CL2019000405A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA PROVOCAR UNA RESPUESTA INMUNE EN ANIMALES QUE DISMINUYE EL RIESGO DE INFECCIÓN POR CHIKUNGUNYA Y VIRUELA, VIRUS ZIKA E INFECCIÓN POR VIRUELA, Y/O CHIKUNGUNYA, VIRUS ZIKA E INFECCIÓN POR VIRUELA. LA COMPOSICIÓN COMPRENDE UN PORTADOR FARMACÉUTICAMENTE ACEPTABLE Y UN POXVIRUS ATENUADO, EN DONDE EL GENOMA DEL POXVIRUS COMPRENDE UNA SECUENCIA DE ÁCIDO NUCLEICO QUE CODIFICA LA POLIPROTEÍNA SUBGENÓMICA 26S DEL VIRUS CHIKUNGUNYA Y/O LA PRME DEL VIRUS ZIKA.
CL2019000405A 2016-08-19 2019-02-14 Vacunas virales. CL2019000405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines

Publications (1)

Publication Number Publication Date
CL2019000405A1 true CL2019000405A1 (es) 2019-06-14

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000405A CL2019000405A1 (es) 2016-08-19 2019-02-14 Vacunas virales.

Country Status (17)

Country Link
US (2) US10905759B2 (es)
EP (2) EP3500280A4 (es)
JP (1) JP2019528271A (es)
KR (1) KR20190050787A (es)
CN (1) CN109862909A (es)
AR (1) AR110624A1 (es)
AU (1) AU2017313450B2 (es)
BR (1) BR112019003181A2 (es)
CA (1) CA3034282A1 (es)
CL (1) CL2019000405A1 (es)
IL (1) IL264893B (es)
MA (1) MA45994A (es)
MX (1) MX2019001919A (es)
NZ (1) NZ750578A (es)
SG (1) SG11201900814QA (es)
TW (1) TWI728173B (es)
WO (1) WO2018032057A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202203966A (zh) * 2020-03-31 2022-02-01 澳大利亞商賽門蒂斯公司 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CN1418951A (zh) 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
ATE403005T1 (de) * 2003-02-18 2008-08-15 Helmholtz Zentrum Muenchen Rekombinantes mva und verfahren zur erzeugung davon
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
CN103200962A (zh) * 2010-09-23 2013-07-10 巴克斯特国际公司 重组病毒载体及用于诱导对黄热病毒的免疫反应的方法
MY193724A (en) * 2013-03-15 2022-10-27 Sementis Ltd Immune modulation
EP3375882B1 (en) * 2013-11-01 2019-10-16 Sementis Limited Viral vector manufacture
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus

Also Published As

Publication number Publication date
KR20190050787A (ko) 2019-05-13
CA3034282A1 (en) 2018-02-22
IL264893B (en) 2022-08-01
US20200009245A1 (en) 2020-01-09
US20210113684A1 (en) 2021-04-22
BR112019003181A2 (pt) 2019-07-16
AU2017313450A1 (en) 2019-02-28
MA45994A (fr) 2021-03-17
EP3500280A1 (en) 2019-06-26
SG11201900814QA (en) 2019-03-28
RU2019107582A3 (es) 2021-03-31
AU2017313450B2 (en) 2024-02-15
IL264893A (es) 2019-04-30
JP2019528271A (ja) 2019-10-10
EP4331676A2 (en) 2024-03-06
WO2018032057A1 (en) 2018-02-22
EP4331676A3 (en) 2024-05-15
TWI728173B (zh) 2021-05-21
CN109862909A (zh) 2019-06-07
MX2019001919A (es) 2019-09-04
NZ750578A (en) 2023-05-26
RU2019107582A (ru) 2020-09-21
AR110624A1 (es) 2019-04-17
EP3500280A4 (en) 2020-05-13
TW201809273A (zh) 2018-03-16
US10905759B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EA201692274A1 (ru) Олигомеры и олигомерные конъюгаты
CL2019000993A1 (es) Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
AR101814A1 (es) Partícula de tipo virus flavivirus
BR112018012642A2 (pt) vacina de calicivírus felino
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
CL2019000405A1 (es) Vacunas virales.
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
UY37198A (es) Vacuna universal para enfermedades virales
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
PH12017500419A1 (en) Recoded arbovirus and vaccines
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
CL2018001201A1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas.
AR107436A1 (es) Vacunas contra el cáncer
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones
PE20212213A1 (es) Cepas de vbi y usos de las mismas